Erlotinib treatment of meningeal carcinomatosis in lung cancer: more is better

Annals of Oncology

Volumn 25, Issue 10, 2014, Pages 2093-2094

  Cessot, A ^a   Blanchet, B ^b   Goldwasser, F ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b Institut Cochin   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; QUINAZOLINE DERIVATIVE;

CASE REPORT; FEMALE; GENETICS; HUMAN; LUNG NEOPLASMS; MENINGEAL CARCINOMATOSIS; METASTASIS; MIDDLE AGED; PATHOLOGY; SECONDARY;

FEMALE; HUMANS; LUNG NEOPLASMS; MENINGEAL CARCINOMATOSIS; MIDDLE AGED; NEOPLASM METASTASIS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84930796940     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu261     Document Type: Letter

References (4)

1. Clarke, J.L., Pao, W., Wu, N., et al. High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer. Neurooncol 99 (2010), 283–286.
2. Grommes, C., Oxnard, G.R., Kris, M.G., et al. “Pulsatile” high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. Neurooncol 13 (2011), 1364–1369.
3. Kuiper, J.L., Heideman, D.A., Thunnissen, E., et al. Eur J Cancer 50 (2014), 1399–1401.
4. Fukudo, M., Ikemi, Y., Togashi, Y., et al. Population pharmacokinetics/pharmacodynamics of erlotinib and pharmacogenomic analysis of plasma and cerebrospinal fluid drug concentrations in Japanese patients with non-small cell lung cancer. Clin Pharmacokinet 52 (2013), 593–609.